Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: The trigeminovascular system plays a central role in migraine, a condition in need of new treatments. The neuropeptide, calcitonin gene-related peptide (CGRP), is proposed as causative in migraine and is the subject of intensive drug discovery efforts. This study explores the expression and functionality of two CGRP receptor candidates in the sensory trigeminal system.
Methods: Receptor expression was determined using Taqman G protein-coupled receptor arrays and immunohistochemistry in trigeminal ganglia (TG) and the spinal trigeminal complex of the brainstem in rat and human. Receptor pharmacology was quantified using sensitive signaling assays in primary rat TG neurons.
Results: mRNA and histological expression analysis in rat and human samples revealed the presence of two CGRP-responsive receptors (AMY1: calcitonin receptor/receptor activity-modifying protein 1 [RAMP1]) and the CGRP receptor (calcitonin receptor-like receptor/RAMP1). In support of this finding, quantification of agonist and antagonist potencies revealed a dual population of functional CGRP-responsive receptors in primary rat TG neurons.
Interpretation: The unexpected presence of a functional non-canonical CGRP receptor (AMY1) at neural sites important for craniofacial pain has important implications for targeting the CGRP axis in migraine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479521 | PMC |
| http://dx.doi.org/10.1002/acn3.197 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PACAP versus CGRP in migraine: From mouse models to clinical translation.
Cephalalgia
September 2025
Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA, USA.
Migraine is a complex neurological disorder involving multiple neuropeptides that modulate nociceptive and sensory pathways. The most studied peptide is calcitonin gene-related peptide (CGRP), which is a well-established migraine trigger and therapeutic target. Recently, another peptide, pituitary adenylate cyclase-activating polypeptide (PACAP), has emerged as an alternative target for migraine therapeutics.
View Article and Find Full Text PDFPerineural botulinum toxin in the management of post-traumatic headache: a case report.
Rev Esp Anestesiol Reanim (Engl Ed)
September 2025
Physical Medicine and Rehabilitation. Universidad del Valle, Cali, Colombia; Interventional Pain Management, Fundalivio, Cali, Colombia.
Post traumatic headache is a common condition that can be managed with pharmacologic interventions or analgesic procedures; however, most evidence is derived from patients with mild trauma, leaving a large gap with regard to patients with moderate or severe trauma who present complex pain. Botulinum toxin plays an increasingly important role in pain management. This neurotoxin acts on different receptors, ranging from TRPV1 (transient receptor potential vanilloid type 1) to CGRP (calcitonin gene-related peptide).
View Article and Find Full Text PDFThe Neurophysiological Effects of Dry Needling: An Update of a Narrative Review.
Am J Phys Med Rehabil
September 2025
Ghent University, Department of Rehabilitation Sciences. Corneel Heymanslaan 10, Ghent, Belgium.
The interest in dry needling as a treatment option for myofascial pain has flourished for the last decades and will probably continue to do so, since multiple clinical effects can be attributed to this technique. However, evidence about the underlying physiological mechanisms of its effects is still underrepresented in scientific research and caution must be taken in generalizing results from acupuncture or animal research. This review offers an overview of the possible mechanisms involved in the pathophysiology of myofascial trigger points, i.
View Article and Find Full Text PDFThe role of Atogepant in migraine prevention: a systematic review and meta-analysis.
BMC Neurol
September 2025
Addis Ababa University, Addis Ababa, Ethiopia.
Background: Atogepant is a CGRP receptor antagonist used in prevention of migraine. This study assesses the safety and efficacy of this drug in management of migraine headaches.
Methods: PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched until March 24, 2025.
Exploring the epigenetic modifications of the RONS-TRPA1-CGRP axis in migraine pathophysiology.
J Headache Pain
September 2025
Faculty of Medicine, Collegium Medicum, The Mazovian University in Plock, Plock, 09-402, Poland.
Background: Epigenetic studies in migraine provided results on the occurrence or lack of epigenetic modifications of genes whose products are important in migraine pathogenesis. However, these studies focus on single genes without analyzing how epigenetic modifications can affect complex signaling pathways. This narrative/hypothesis review aims to provide information on how the reactive oxygen and nitrogen species (RONS)-transient receptor potential cation channel subfamily A member 1 (TRPA1)-calcitonin gene-related peptide (CGRP) axis functions, suggesting that its epigenetic modifications could be a significant factor in migraine pathophysiology.
View Article and Find Full Text PDF